Switching from under-the-skin injections of Takhzyro (lanadelumab) to oral capsules of Orladeyo (berotralstat) was generally safe and kept…
Articles by Marta Figueiredo, PhD
Firazyr (icatibant injection) appears to be at least as safe and effective at controlling swelling attacks in hereditary angiodema…
Regulatory health agencies in Canada and Switzerland have approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) as the first daily oral therapy…
A fully assembled, prefilled syringe form of Takeda’s Takhzyro (lanadelumab), approved to prevent swelling attacks in adults and children,…
About one year of treatment with Takhzyro (lanadelumab) safely and effectively lowered the frequency of swelling attacks, while improving…
Long-term treatment with Orladeyo (berotralstat) at its approved 150 mg daily dose reduces the rate of swelling attacks significantly…
The U.S. Food and Drug Administration (FDA) has approved the use of a prefilled syringe of Takeda’s Takhzyro…
The richness and diversity of the gut’s microbial community, or microbiota, are significantly reduced in people with hereditary angioedema…
Excess blood levels of uric acid — a normal body waste product — and Hashimoto’s disease, an autoimmune condition, may…
Ionis Pharmaceuticals has launched a registrational Phase 3 clinical trial to evaluate the safety and effectiveness of its investigational therapy…